Teladoc Health, Inc. (TDOC) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
↓
15.13
↓-96% vs avg
5yr avg: 368.47
30Y Low14.9·High14.9
P/FCF
↓
4.40
↓-83% vs avg
5yr avg: 25.58
30Y Low4.3·High77.7
P/B Ratio
↓
0.89
↓-26% vs avg
5yr avg: 1.20
30Y Low0.9·High5.9
ROE
↓
-13.9%
↓+69% vs avg
5yr avg: -45.5%
30Y Low-149%·High-3%
Debt/EBITDA
↓
10.38
↓-93% vs avg
5yr avg: 148.36
30Y Low10.4·High10.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TDOC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Teladoc Health, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 4.4x P/FCF, 83% below the 5-year average of 25.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.2B | $1.6B | $3.5B | $3.8B | $14.4B | $18.1B | $6.0B | $3.3B | $1.9B | $698M |
| Enterprise Value | $1.5B | $1.5B | $1.8B | $4.0B | $4.5B | $14.8B | $18.8B | $6.0B | $3.3B | $2.1B | $693M |
| P/E Ratio → | -6.11 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.50 | 0.49 | 0.60 | 1.36 | 1.59 | 7.09 | 16.54 | 10.87 | 7.81 | 8.28 | 5.67 |
| P/B Ratio | 0.89 | 0.89 | 1.04 | 1.52 | 1.65 | 0.90 | 1.14 | 5.93 | 3.22 | 3.46 | 3.03 |
| P/FCF | 4.40 | 4.32 | 5.48 | 18.31 | 22.10 | 77.70 | — | 317.09 | — | — | — |
| P/OCF | 4.27 | 4.19 | 5.28 | 10.13 | 20.17 | 74.28 | — | 201.37 | — | — | — |
P/E links to full P/E history page with 30-year chart
TDOC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Teladoc Health, Inc.'s enterprise value stands at 15.1x EBITDA, 96% below its 5-year average of 368.5x. The Healthcare sector median is 14.4x, placing the stock at a 5% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.59 | 0.71 | 1.54 | 1.86 | 7.28 | 17.22 | 10.79 | 7.79 | 8.99 | 5.63 |
| EV / EBITDA | 15.13 | 14.90 | — | 722.04 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 5.23 | 6.49 | 20.73 | 25.97 | 79.79 | — | 314.77 | — | — | — |
TDOC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Teladoc Health, Inc. earns an operating margin of -10.4%. A negative ROE of -13.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.5% | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% | 64.3% | 66.7% | 69.2% | 73.6% | 74.0% |
| Operating Margin | -10.4% | -10.4% | -39.7% | -9.6% | -567.3% | -13.1% | -46.3% | -14.5% | -17.0% | -32.3% | -50.9% |
| Net Profit Margin | -7.9% | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | -44.3% | -17.9% | -23.2% | -45.8% | -60.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -13.9% | -13.9% | -52.5% | -9.5% | -148.8% | -2.7% | -5.7% | -9.8% | -12.4% | -27.0% | -36.3% |
| ROA | -6.1% | -6.1% | -25.3% | -4.8% | -121.8% | -2.4% | -5.0% | -6.3% | -8.3% | -18.9% | -27.8% |
| ROIC | -11.5% | -11.5% | -33.5% | -6.5% | -105.5% | -1.2% | -4.3% | -6.1% | -6.2% | -11.9% | -25.0% |
| ROCE | -10.0% | -10.0% | -31.2% | -6.0% | -125.8% | -1.5% | -5.3% | -5.4% | -6.3% | -14.1% | -25.4% |
TDOC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Teladoc Health, Inc. carries a Debt/EBITDA ratio of 10.4x, which is highly leveraged (216% above the sector average of 3.3x). Net debt stands at $259M ($1.0B total debt minus $781M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.75 | 0.75 | 1.06 | 0.68 | 0.69 | 0.08 | 0.09 | 0.46 | 0.41 | 0.37 | 0.19 |
| Debt / EBITDA | 10.38 | 10.38 | — | 286.33 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.19 | 0.19 | 0.20 | 0.29 | 0.02 | 0.05 | -0.04 | -0.01 | 0.29 | -0.02 |
| Net Debt / EBITDA | 2.59 | 2.59 | — | 84.27 | — | — | — | — | — | — | — |
| Debt / FCF | — | 0.91 | 1.01 | 2.42 | 3.87 | 2.08 | — | -2.31 | — | — | — |
| Interest Coverage | -10.95 | -10.95 | -8.77 | -9.45 | -9.91 | -2.95 | -6.98 | -2.51 | -2.53 | -3.56 | -20.30 |
TDOC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Teladoc Health, Inc.'s current ratio of 2.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.54x to 2.69x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | 2.69 | 1.77 | 3.54 | 3.22 | 3.70 | 3.19 | 6.52 | 8.53 | 3.87 | 3.93 |
| Quick Ratio | 2.59 | 2.59 | 1.73 | 3.47 | 3.07 | 3.48 | 3.02 | 6.52 | 8.53 | 3.87 | 3.93 |
| Cash Ratio | 1.93 | 1.93 | 1.38 | 2.67 | 2.30 | 2.71 | 2.36 | 5.73 | 7.66 | 3.03 | 3.12 |
| Asset Turnover | — | 0.82 | 0.73 | 0.59 | 0.51 | 0.11 | 0.06 | 0.35 | 0.27 | 0.28 | 0.41 |
| Inventory Turnover | 20.20 | 20.20 | 19.70 | 25.75 | 13.20 | 8.90 | 6.92 | — | — | — | — |
| Days Sales Outstanding | — | 29.09 | 31.81 | 32.27 | 35.74 | 34.14 | 56.48 | 37.57 | 38.05 | 42.39 | 40.92 |
TDOC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Teladoc Health, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 22.7% | 23.1% | 18.2% | 5.5% | 4.5% | 1.3% | — | 0.3% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $176M | $171M | $165M | $161M | $157M | $91M | $72M | $66M | $55M | $42M |
Peer Comparison
Compare TDOC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TDOCYou | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 AMWL | $129M | -1.3 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 DOCS | $5B | 23.5 | 21.1 | 19.6 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 OMCL | $2B | 978.1 | 23.6 | 22.7 | 42.5% | 0.4% | 0.2% | 0.3% | 2.4 |
 GDRX | $973M | 33.3 | 4.0 | 5.9 | 82.1% | 13.4% | 4.5% | 13.0% | 0.3 |
 TALK | $868M | 129.5 | 137.8 | — | 43.0% | 1.4% | 6.6% | 3.9% | — |
 OPRX | $124M | 24.6 | 6.5 | 6.6 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 UNH | $336B | 27.9 | 16.7 | 20.9 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 |
 CVS | $111B | 62.8 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See TDOC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TDOC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TDOC vs AMWL
Side-by-side business, growth, and profitability comparison vs American Well Corporation.
Start ComparisonTDOC — Frequently Asked Questions
Quick answers to the most common questions about buying TDOC stock.
What is Teladoc Health, Inc.'s P/E ratio?
Teladoc Health, Inc.'s current P/E ratio is -6.1x. This places it at the 50th percentile of its historical range.
What is Teladoc Health, Inc.'s EV/EBITDA?
Teladoc Health, Inc.'s current EV/EBITDA is 15.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.9x.
What is Teladoc Health, Inc.'s ROE?
Teladoc Health, Inc.'s return on equity (ROE) is -13.9%. The historical average is -34.4%.
Is TDOC stock overvalued?
Based on historical data, Teladoc Health, Inc. is trading at a P/E of -6.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Teladoc Health, Inc.'s profit margins?
Teladoc Health, Inc. has 69.5% gross margin and -10.4% operating margin.
How much debt does Teladoc Health, Inc. have?
Teladoc Health, Inc.'s Debt/EBITDA ratio is 10.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.